HLS Therapeutics Inc
TSX:HLS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
HLS Therapeutics Inc
TSX:HLS
|
CA |
|
S
|
Shenzhen Dynanonic Co Ltd
SZSE:300769
|
CN |
|
N
|
NK Lukoil PAO
LSE:LKOH
|
RU |
|
N
|
Nawarat Patanakarn PCL
SET:NWR
|
TH |
|
V
|
Vikas Ecotech Ltd
BSE:530961
|
IN |
|
M
|
Maxicity Holdings Ltd
HKEX:2295
|
HK |
|
B
|
BizConf Telecom Co Ltd
SZSE:300578
|
CN |
|
Oncolytics Biotech Inc
TSX:ONC
|
CA |
|
Kohinoor Foods Ltd
NSE:KOHINOOR
|
IN |
|
GSD Holding AS
IST:GSDHO.E
|
TR |
|
Turkcell Iletisim Hizmetleri AS
IST:TCELL.E
|
TR |
|
W
|
WiSoL Co Ltd
KOSDAQ:122990
|
KR |
HLS Therapeutics Inc
HLS Therapeutics, Inc. operates as a pharmaceutical company. The company is headquartered in Etobicoke, Ontario and currently employs 92 full-time employees. The firm is focused on developing clinically differentiated pharmaceutical products in the specialty central nervous system (CNS) and cardiovascular (CV) markets. Its products include Vascepa, Trinomia, Clozaril, CSAN Pronto, PERSERIS and MyCare Psychiatry/MyCare Insite. Its lead product, Clozaril, is an atypical antipsychotic indicated in the management of symptoms of treatment-resistant schizophrenia for the Canadian and United States markets. CSAN Pronto is a capillary point-of-care medical device designed to enhance and simplify the mandatory safety blood monitoring process for patients that are prescribed Clozaril. Vascepa capsules reduce the risk of cardiovascular events, such as cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, coronary revascularization, or hospitalization for unstable angina in statin-treated patients with elevated triglycerides.
HLS Therapeutics, Inc. operates as a pharmaceutical company. The company is headquartered in Etobicoke, Ontario and currently employs 92 full-time employees. The firm is focused on developing clinically differentiated pharmaceutical products in the specialty central nervous system (CNS) and cardiovascular (CV) markets. Its products include Vascepa, Trinomia, Clozaril, CSAN Pronto, PERSERIS and MyCare Psychiatry/MyCare Insite. Its lead product, Clozaril, is an atypical antipsychotic indicated in the management of symptoms of treatment-resistant schizophrenia for the Canadian and United States markets. CSAN Pronto is a capillary point-of-care medical device designed to enhance and simplify the mandatory safety blood monitoring process for patients that are prescribed Clozaril. Vascepa capsules reduce the risk of cardiovascular events, such as cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, coronary revascularization, or hospitalization for unstable angina in statin-treated patients with elevated triglycerides.
This earnings call has not been analyzed yet.
If you’d like us to analyze this earnings call, click the "Request Earnings Call Analysis" button below.
